Ares Financial Consulting, LLC
Position in NBIX — Neurocrine Biosciences Inc
CIK 2106717
CALABASAS, CA
Position in NBIX
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$4,887
+$1,726 QoQ
Shares Held
29
+20.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#710
of 768 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Ares Financial Consulting, LLC holds $67,326 across 12 Drug Manufacturers - Specialty & Generic names. NBIX ranks #6 (7.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TAK |
Takeda Pharmaceutical Co Ltd
|
1,204 | $19,300 | |
| 2 | VTRS |
Viatris Inc
|
810 | $12,862 | |
| 3 | HLN |
Haleon plc
|
960 | $8,956 | |
| 4 | ZTS |
Zoetis Inc.
|
87 | $6,251 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
153 | $5,183 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
This page
|
29 | $4,887 | |
| 7 | UTHR |
UNITED THERAPEUTICS Corp
|
7 | $3,792 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
17 | $1,885 |
All Filings in NBIX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,887 | 29 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $3,161 | 24 | Shares | Sole | 2026-04-02 | |
| 2025-12-31 | $3,403 | 24 | Shares | Sole | 2026-01-30 | |
| No filing history on record for this holder in this stock. | ||||||